Autolus Therapeutics (NASDAQ:AUTL) Issues Earnings Results

Autolus Therapeutics (NASDAQ:AUTL) issued its quarterly earnings data on Wednesday. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.07), Zacks reports. The business had revenue of $21.14 million for the quarter, compared to analysts’ expectations of $21.08 million.

Autolus Therapeutics Trading Down 5.9%

Autolus Therapeutics stock traded down $0.08 during mid-day trading on Thursday, reaching $1.28. The company’s stock had a trading volume of 3,132,639 shares, compared to its average volume of 2,367,418. Autolus Therapeutics has a twelve month low of $1.11 and a twelve month high of $3.45. The business has a 50 day moving average price of $1.51 and a 200-day moving average price of $1.81. The firm has a market cap of $340.66 million, a price-to-earnings ratio of -1.52 and a beta of 1.84.

Analysts Set New Price Targets

AUTL has been the topic of several recent analyst reports. Wall Street Zen upgraded Autolus Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 16th. William Blair restated an “outperform” rating on shares of Autolus Therapeutics in a report on Wednesday, September 24th. Wells Fargo & Company cut their target price on Autolus Therapeutics from $6.00 to $5.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Autolus Therapeutics in a research note on Wednesday, October 8th. Finally, Needham & Company LLC restated a “buy” rating and issued a $10.00 price target on shares of Autolus Therapeutics in a research note on Monday, November 3rd. Six analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $9.12.

Hedge Funds Weigh In On Autolus Therapeutics

A number of large investors have recently bought and sold shares of the business. Schroder Investment Management Group lifted its holdings in shares of Autolus Therapeutics by 133.7% in the 3rd quarter. Schroder Investment Management Group now owns 8,433,253 shares of the company’s stock worth $13,409,000 after purchasing an additional 4,824,763 shares during the last quarter. Bank of America Corp DE increased its position in Autolus Therapeutics by 2,891.7% in the second quarter. Bank of America Corp DE now owns 975,135 shares of the company’s stock worth $2,223,000 after buying an additional 942,540 shares during the period. UBS Group AG lifted its stake in Autolus Therapeutics by 16.1% in the third quarter. UBS Group AG now owns 410,662 shares of the company’s stock valued at $669,000 after buying an additional 56,995 shares during the last quarter. The Manufacturers Life Insurance Company lifted its stake in Autolus Therapeutics by 41.6% in the second quarter. The Manufacturers Life Insurance Company now owns 38,419 shares of the company’s stock valued at $88,000 after buying an additional 11,289 shares during the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of Autolus Therapeutics by 90.5% during the second quarter. Geode Capital Management LLC now owns 164,314 shares of the company’s stock valued at $375,000 after acquiring an additional 78,058 shares during the period. Institutional investors own 72.83% of the company’s stock.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.